LEAP THERAPEUTICS, INC.

Analyst Reco. Leap Therapeutics, Inc.

Equities

LPTX

US52187K2006

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
3.25 ^USD	+2.52%		+16.07%	-21.59%

04-10	Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP	CI
03-19	Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating	03-19	MT
Mizuho Securities Adjusts Price Target on Leap Therapeutics to $12 From $20, Maintains Buy Rating	11-20	MT
Baird Lowers Price Target on Leap Therapeutics to $20 From $30, Maintains Outperform Rating	23-08-15	MT
Raymond James Adjusts Price Target on Leap Therapeutics to $18.50 From $17, Maintains Outperform Rating	23-07-13	MT
Raymond James Adjusts Price Target on Leap Therapeutics to $17 From $20, Keeps Outperform Rating	23-06-23	MT
Raymond James Adjusts Price Target on Leap Therapeutics to $2 From $2.50, Maintains Outperform Rating	23-03-27	MT
Mizuho Adjusts Price Target on Leap Therapeutics to $2 From $3, Maintains Buy Rating	23-03-17	MT
Mizuho Securities Adjusts Price Target on Leap Therapeutics to $3 From $6, Maintains Buy Rating	23-01-27	MT
HC Wainwright Lowers Price Target on Leap Therapeutics to $2.50 From $4, Maintains Buy Rating	23-01-18	MT
Raymond James Adjusts Price Target on Leap Therapeutics to $2.50 From $3.50, Maintains Outperform Rating	22-11-11	MT
Raymond James Adjusts Leap Therapeutics' Price Target to $3 from $4, Keeps Outperform Rating	22-07-13	MT
Piper Sandler Adjusts Leap Therapeutics' Price Target to $4 From $6, Reiterates Overweight Rating	22-05-31	MT
Piper Sandler Adjusts Leap Therapeutics' Price Target to $6 From $5, Reiterates Overweight Rating	22-01-24	MT
LEAP THERAPEUTICS : Mizuho Securities Starts Leap Therapeutics at Buy With $6 Price Target	21-10-04	MT
LEAP THERAPEUTICS : Raymond James Lifts Leap Therapeutics' Price Target to $4 from $3, Keeps Outperform Rating	21-09-14	MT
ANALYST RECOMMENDATIONS : American express, CrowdStrike, Five Below, J.M. Smucker, Lululemon...	21-06-07
LEAP THERAPEUTICS : Baird Starts Leap Therapeutics at Outperform with $5 Price Target	21-06-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer